INOVAIT to announce latest Pilot Fund recipients at ALL IN 2025

Aug 26, 2025
ALL IN

INOVAIT, Canada’s membership network promoting image-guided therapy (IGT) and artificial intelligence (AI) technology innovations, announced that they will present their latest Pilot Fund recipients at SCALE AI’s 2025 ALL IN event at the Palais des congrès in Montreal, Quebec, from September 24-25.

The Pilot Fund is a non-dilutive funding program facilitated by INOVAIT. It provides up to $125,000 in contributions for research and development (R&D) projects lasting 9 to 15 months. The Pilot Fund promotes the commercial translation of R&D within the medical device and digital health sectors. These projects have the potential to transform patient outcomes and reduce the overall cost of healthcare in Canada.

Share this on social media

Learn more about the network

INOVAIT launches Canada-wide medtech job board to connect talent with innovation

INOVAIT launches Canada-wide medtech job board to connect talent with innovation

Developed in response to increasing demand from our members and job seekers, the INOVAIT Network Job Board offers job seekers direct access to high-impact roles at some of the country’s top companies working in emerging medical technologies. Updated daily, the platform features listings from across the INOVAIT network and is designed to help talented professionals launch or advance their careers in a home-grown company right here in Canada.

Cohesic flips the script on incorporating AI into healthcare

Cohesic flips the script on incorporating AI into healthcare

Jordan Engbers, Chief Science Officer of Cohesic, a data scientist who spent years in clinical research, is painfully aware of the chasm between the promise and reality of AI in healthcare. While an AI model might work within a study where researchers systematically gather, clean up, and standardize the data, real-world healthcare data is often too messy and unreliable to use for clinical decisions.

Seeing beneath the surface: How MIMOSA is transforming wound care

Seeing beneath the surface: How MIMOSA is transforming wound care

Dr. Karen Cross, a plastic and reconstructive surgeon and CEO of MIMOSA Diagnostics, saw countless patients with diabetes and chronic wounds in her clinic. People with diabetes have an increased risk of developing pressure wounds due to complications like poor circulation and nerve damage. Many of her patients came into her clinic too late to prevent complications and ultimately had lower extremity amputations to prevent fatal infections.